Symptom Management and Lifestyle Modifications in Multiple Sclerosis

CONTINUUM Lifelong Learning in Neurology

Volumn 22, Issue 3, 2016, Pages 815-836

  Coyle, Patricia K ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEDICAL CANNABIS; VITAMIN D;

ALCOHOL CONSUMPTION; BLADDER DYSFUNCTION; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM FUNCTION; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DIET; EXERCISE; FATIGUE; HUMAN; HYGIENE; LIFESTYLE MODIFICATION; MENTAL DISEASE; MENTAL FUNCTION; MOOD DISORDER; MULTIPLE SCLEROSIS; QUALITY OF LIFE; REVIEW; SLEEP QUALITY; SOCIAL INTERACTION; SPASTICITY; STRESS; TEMPERATURE; TOBACCO USE; ADULT; CASE REPORT; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; DRINKING BEHAVIOR; FEMALE; HEALTHY LIFESTYLE; MALE; MIDDLE AGED; PHYSIOLOGY; RISK REDUCTION; SMOKING;

ADULT; ALCOHOL DRINKING; DISEASE MANAGEMENT; EXERCISE; FATIGUE; FEMALE; HEALTHY LIFESTYLE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RISK REDUCTION BEHAVIOR; SMOKING;

EID: 84974588085     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/CON.0000000000000325     Document Type: Review

References (94)

1. Patti F, Vila C. Symptoms, prevalence and impact of multiple sclerosis in younger patients: a multinational survey. Neuroepidemiology 2014;42(4):211-218. doi:10.1159/000360423.
2. Kister I, Bacon TE, Chamot E, et al. Natural history of multiple sclerosis symptoms. Int J MS Care 2013;15(3):146-158. doi:10.7224/1537-2073.2012-053.
3. Hobart J, Lamping D, Fitzpatrick R, et al. The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure. Brain 2001;124(pt 5):962-973.
4. Haab F, Richard F, Amarenco G, et al. Comprehensive evaluation of bladder and urethral dysfunction symptoms: development and psychometric validation of the Urinary Symptom Profile (USP) questionnaire. Urology 2008;71(4):646-656. doi:10.1016/j.urology.2007.11.100.
5. Bladder Control Scale (BLCS). National Multiple Sclerosis Society website. www. nationalmssociety.org/For-Professionals/Researchers/Resources-for-Researchers/Clinical-Study-Measures/Bladder-Control-Scale-(BLCS). Accessed March 30, 2016.
6. Bowel Control Scale (BWCS). National Multiple Sclerosis website. www. nationalmssociety.org/For-Professionals/Researchers/Resources-for-Researchers/Clinical-Study-Measures/Bowel-Control-Scale-(BWCS). Accessed March 30, 2016.
7. Smith A. Symbol Digit Modalities Test. Los Angeles, CA: Western Psychological Services; 1982.
8. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46(10):1121-1123.
9. Modified Fatigue Impact Scale (MFIS). National Multiple Sclerosis Society website. www.nationalmssociety.org/For-Professionals/Researchers/Resources-for-Researchers/Clinical-Study-Measures/Modified-Fatigue-Impact-Scale-(MFIS). Accessed March 30, 2016.
10. Timed 25-Foot Walk (T25-FW). National Multiple Sclerosis Society website. www. nationalmssociety.org/For-Professionals/Researchers/Resources-for-Researchers/Clinical-Study-Measures/Timed-25-Foot-Walk-(T25-FW). Accessed March 30, 2016.
11. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4(6):561-571.
12. Two question screen. www.uphp.com/wp-content/uploads/2013/10/TwoQuestion Screen.pdf. Published December 4, 2002. Accessed March 30, 2016.
13. Hospital Anxiety and Depression Scale. www.scalesandmeasures.net/files/files/HADS.pdf. Accessed April 6, 2016.
14. Generalized Anxiety Disorder 7-item (GAD-7) scale. www.integration.samhsa.gov/clinical-practice/GAD708.19.08Cartwright.pdf. Accessed March 30, 2016.
15. Moore SR, Gresham LS, Bromberg MB, et al. A self report measure of affective lability. J Neurol Neurosurg Psychiatry 1997;63(1):89-93.
16. Short Form McGill Pain Questionnaire. www. npcrc.org/files/news/mcgill-pain-inventory. pdf. Accessed March 30, 2016.
17. Brief Pain Inventory (Short Form). www. npcrc.org/files/news/briefpain-short.pdf. Published 1991. Revised July 1, 2005. Accessed March 30, 2016.
18. The Brief Pain Inventory. www.npcrc.org/files/news/briefpain-long.pdf. Published 1991. Accessed March 30, 2016.
19. MOS Pain Effects Scale (PES). National Multiple Sclerosis Society website. www. nationalmssociety.org/For-Professionals/Researchers/Resources-for-Researchers/Clinical-Study-Measures/MOS-Pain-Effects-Scale-(PES). Accessed March 30, 2016.
20. Sexual Satisfaction Scale (SSS). National Multiple Sclerosis website. www. nationalmssociety.org/For-Professionals/Researchers/Resources-for-Researchers/Clinical-Study-Measures/Sexual-Satisfaction-Scale-(SSS). Accessed March 30, 2016.
21. Buysse DJ, Reynolds III CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28(2):193-213.
22. Epworth Sleepiness Scale. epworthsleepinessscale.com/epworth-sleepiness-scale.pdf. Accessed March 30, 2016.
23. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67(2): 206-207.
24. Impact of Visual Impairment Scale (IVIS). National Multiple Sclerosis Society website. www.nationalmssociety.org/For-Professionals/Researchers/Resources-for-Researchers/Clinical-Study-Measures/Impact-of-Visual-Impairment-Scale-(IVIS). Accessed March 30, 2016.
25. Berger JR, Pocoski J, Preblick R, Boklage S. Fatigue heralding multiple sclerosis. Mult Scler 2013;19(11):1526-1532. doi:10.1177/1352458513477924.
26. Runia TF, Jafari N, Siepman DA, Hintzen RQ. Fatigue at a time of CIS is an independent predictor of a subsequent diagnosis of multiple sclerosis. J Neurol Neurosurg Psychiatry 2015;86(5):543-546. doi:10.1136/jnnp-2014-308374.
27. Solaro C, Trabucco E, Messmer Uccelli M. Pain and multiple sclerosis: pathophysiology and treatment. Curr Neurol Neurosci Rep 2013;13(1):320. doi:10.1007/s11910-012-0320-5.
28. Gronseth G, Cruccu G, Alksne J, et al. (2008) Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): a report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology 2008;71(15):1183-1190. doi:10.1212/01.wnl.0000326598.83183.04.
29. Okuda DT, Melmed K, Matsuwaki T, et al. Central neuropathic pain in MS is due to distinct thoracic spinal cord lesions. Ann Clin Transl Neurol 2014;1(8):554-561. doi:10.1002/acn3.85.
30. Sumowski JF, Leavitt VM. Cognitive reserve in multiple sclerosis. Mult Scler 2013;19(9): 1122-1127. doi:10.1177/1352458513498834.
31. Sumowski JF. Cognitive reserve as a useful concept for early intervention research in multiple sclerosis. Front Neurol 2015;6:176. doi:10.3389/fneur.2015.00176.
32. Rocca MA, Amato MP, De Stefano N, et al. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol 2015;14(3):302-317. doi:10.1016/S1474-4422(14)70250-9.
33. Staffen W, Mair A, Zaune H, et al. Cognitive function and fMRI in patients with multiple sclerosis: evidence for compensatory cortical activation during an attention task. Brain 2002;125(pt 6):1275-1282.
34. Wiens AN, Fulle KH, Crossen JR. Paced Auditory Serial Addition Test: adult norms and moderator variables. J Clin Exp Neuropsychol 1997;19(4):473-483.
35. Bonavita S, Sacco R, Della Corte M, et al. Computer-aided cognitive rehabilitation improves cognitive performances and induces brain functional connectivity changes in relapsing remitting multiple sclerosis patients: an exploratory study. J Neurol 2015;262(1):91-100. doi:10.1007/s00415-014-7528-z.
36. Dresler M, Sandberg A, Ohla K, et al. Non-pharmacological cognitive enhancement. Neuropharmacology 2013;64:529-543. doi:10.1016/j.neuropharm.2012.07.002.
37. He D, Zhang Y, Dong S, et al. Pharmacological treatment for memory disorder in multiple sclerosis. Cochrane Database Syst Rev 2013;12:CD008876. doi:10.1002/14651858.CD008876.pub3.
38. Minden SL, Feinstein S, Kalb RC, et al. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014;82(2):174-181. doi:10.1212/WNL.0000000000000013.
39. Labiano-Fontcuberta A, Aladro Y, Martínez-Ginés ML, et al. Psychiatric disturbances in radiologically isolated syndrome. J Psychiatr Res 2015;68:309-315. doi:10.1016/j.jpsychires.2015.05.008.
40. Ghezzi A, Mutta E, Bianchi F, et al. Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances (published online ahead of print November 27, 2015). Neurol Sci. doi:10.1007/s10072-015-2415-7.
41. Fox RJ, Bacon TE, Chamot E, et al. Prevalence of multiple sclerosis symptoms across lifespan: data from the NARCOMS Registry. Neurodegener Dis Manag 2015;5(6 suppl): 3-10. doi:10.2217/nmt.15.55.
42. Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol 2015;14(7): 720-732. doi:10.1016/S1474-4422(15)00070-8.
43. Gallien P, Amarenco G, Benoit N, et al. Cranberry versus placebo in the prevention of urinary infections in multiple sclerosis: a multicenter, randomized, placebo-controlled, double-blind trial. Mult Scler 2014;20(9): 1252-1259. doi:10.1177/1352458513517592.
44. Sadiq A, Brucker BM. Management of neurogenic lower urinary tract dysfunction in multiple sclerosis patients. Curr Urol Rep 2015;16(7):44. doi:10.1007/s11934-015-0519-5.
45. Feinstein A, Freeman J, Lo AC. Treatment of progressive multiple sclerosis: what works, what does not, and what is needed. Lancet Neurol 2015;14(2):194-207. doi:10.1016/S1474-4422(14)70231-5.
46. Gironi M, Martinelli-Boneschi F, Sacerdote P, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler 2008;14(8):1076-1083. doi:10.1177/1352458508095828.
47. Hedman AM, van Haren NE, Schnack HG, et al. Human brain changes across the life span: a review of 56 longitudinal magnetic resonance imaging studies. Hum Brain Mapp 2012;33(8):1987-2002. doi:10.1002/hbm.21334.
48. Aubert-Broche B, Fonov V, Narayanan S, et al. Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth. Neurology 2014;83(23): 2140-2146. doi:10.1212/WNL. 0000000000001045.
49. Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol 2012;11(11):1006-1012. doi:10.1016/S1474-4422(12)70191-6.
50. Tutuncu M, Tang J, Zeid NA, et al. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler 2013;19(2):188-198. doi:10.1177/1352458512451510.
51. Manzel A, Muller DN, Hafler DA, et al. Role of "Western diet" in inflammatory autoimmune diseases. Curr Allergy Asthma Rep 2014;14(1):404. doi:10.1007/s11882-013-0404-6.
52. Kiliaan AJ, Arnoldussen IA, Gustafson DR. Adipokines: a link between obesity and dementia? Lancet Neurol 2014;13(9): 913-923. doi:10.1016/S1474-4422(14)70085-7.
53. Marques EL, Halpern A, Corrêa Mancini M, et al. Changes in neuropsychological tests and brain metabolism after bariatric surgery. J Clin Endocrinol Metab 2014;99(11): E2347-E2352. doi:10.1210/jc.2014-2068.
54. Wesnes K, Riise T, Casetta I, et al. Body size and the risk of multiple sclerosis in Norway and Italy: the EnvIMS Study. Mult Scler 2015;21(4):388-395. doi:10.1177/1352458514546785.
55. Kavak KS, Teter BE, Hagemeier J, et al. Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset. Mult Scler 2015;21(7):858-865. doi:10.1177/1352458514555787.
56. Hedström AK, Lima Bomfim I, Hillert J, et al. Obesity interacts with infectious mononucleosis in risk of multiple sclerosis. Eur J Neurol 2015;22(3):578-e38. doi:10.1111/ene.12620.
57. Hedström AK, Lima Bomfim I, Barcellos L, et al. Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. Neurology 2014;82(10):865-872. doi:10.1212/WNL.0000000000000203.
58. Naik P, Fofaria N, Prasad S, et al. Oxidative and pro-inflammatory impact of regular and denicotinized cigarettes on blood brain barrier endothelial cells: is smoking reduced or nicotine-free products really safe? BMC Neurosci 2014;15:51. doi:10.1186/1471-2202-15-51.
59. Hedström AK, Hillert J, Olsson T, Alfredsson L. Smoking and multiple sclerosis susceptibility. Eur J Epidemiol 2013;28(11):867-874. doi:10.1007/s10654-013-9853-4.
60. Manouchehrinia A, Tench CR, Maxted J, et al. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. Brain 2013;136(pt 7): 2298-2304. doi:10.1093/brain/awt139.
61. Ozcan ME, Ince B, Bingö l A, et al. Association between smoking and cognitive impairment in multiple sclerosis. Neuropsychiatr Dis Treat 2014;10:1715-1719. doi:10.2147/NDT.S68389.
62. Manouchehrinia A, Weston M, Tench CR, et al. Tobacco smoking and excess mortality in multiple sclerosis: a cohort study. J Neurol Neurosurg Psychiatry 2014;85(10):1091-1095. doi:10.1136/jnnp-2013-307187.
63. Briggs FB, Acuna B, Shen L, et al. Smoking and risk of multiple sclerosis: evidence of modification by NAT1 variants. Epidemiology 2014;25(4):605-614. doi:10.1097/EDE.0000000000000089.
64. Hedström A, Alfredsson L, Lundkvist Ryner M, et al. Smokers run increased risk of developing anti-natalizumab antibodies. Mult Scler 2013;20(8):1081-1085. doi:10.1177/1352458513515086.
65. Hedström AK, Hillert J, Olsson T, Alfredsson L. Alcohol as a modifiable lifestyle factor affecting multiple sclerosis risk. JAMA Neurol 2014;71(3):300-305. doi:10.1001/jamaneurol.2013.5858.
66. Pakpoor J, Goldacre R, Disanto G, et al. Alcohol misuse disorders and multiple sclerosis risk. JAMA Neurol 2014;71(9): 1188-1189. doi:10.1001/jamaneurol. 2014.1795.
67. Wang YJ, Li R, Yan JW, et al. The epidemiology of alcohol consumption and multiple sclerosis: a review. Neurol Sci 2015;36(2):189-196. doi:10.1007/s10072-014-2007-y.
68. Thouvenot E, Orsini M, Daures JP, Camu W. Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis. Eur J Neurol 2015;22(3):564-569. doi:10.1111/ene.12617.
69. Burton JM, Costello FE. Vitamin D in multiple sclerosis and central nervous system demyelinating diseaseVa review. J Neuroophthalmol 2015;35(2):194-200. doi:10.1097/WNO.0000000000000256.
70. Correale J, Gaitán MI. Multiple sclerosis and environmental factors: the role of vitamin D, parasites, and Epstein-Barr virus infection. Acta Neurol Scand Suppl 2015;132(199): 46-55. doi:10.1111/ane.12431.
71. Sundström P, Salzer J. Vitamin D and multiple sclerosisVfrom epidemiology to prevention. Acta Neurol Scand Suppl 2015;132(199):56-61. doi:10.1111/ane.12432.
72. Cortese M, Riise T, Bjørnevik K, et al. Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: the EnvIMS study. Mult Scler 2015. doi:10.1177/1352458515578770.
73. Ascherio A, Munger KL, White R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 2014;71(3):306-314. doi:10.1001/jamaneurol.2013.5993.
74. Mielcarz DW, Kasper LH. The gut microbiome in multiple sclerosis. Curr Treat Options Neurol 2015;17(4):344. doi:10.1007/s11940-015-0344-7.
75. Riccio P, Rossano R. Nutrition facts in multiple sclerosis. ASN Neuro 2015;7(1):pii: 1759091414568185. doi:10.1177/1759091414568185.
76. Smyth A, Dehghan M, O'Donnell M, et al. Healthy eating and reduced risk of cognitive decline: a cohort from 40 countries. Neurology 2015;84(22):2258-2265. doi:10.1212/WNL.0000000000001638.
77. Farez MF, Fiol MP, Gaitán MI, et al. Sodium intake is associated with increased disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 2015;86(1):26-31. doi:10.1136/jnnp-2014-307928.
78. Pilutti LA, Platta ME, Motl RW, Latimer-Cheung AE. The safety of exercise training in multiple sclerosis: a systematic review. J Neurol Sci 2014;343(1-2):3-7. doi:10.1016/j.jns.2014.05.016.
79. Giesser BS. Exercise in the management of persons with multiple sclerosis. Ther Adv Neurol Disord 2015;8(3):123-130. doi:10.1177/1756285615576663.
80. Mulero P, Almansa R, Neri MJ, et al. Improvement of fatigue in multiple sclerosis by physical exercise is associated to modulation of systemic interferon response. J Neuroimmunol 2015;280:8-11. doi:10.1016/j.jneuroim.2015.01.011.
81. Adamson BC, Ensari I, Motl RW. Effect of exercise on depressive symptoms in adults with neurologic disorders: a systematic review and meta-analysis. Arch Phys Med Rehabil 2015;96(7):1329-1338. doi:10.1016/j.apmr.2015.01.005.
82. Briken S, Gold SM, Patra S, et al. Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial. Mult Scler 2014;20(3):382-390. doi:10.1177/1352458513507358.
83. Yaffe K, Falvey CM, Hoang T. Connections between sleep and cognition in older adults. Lancet Neurol 2014; 13(10):1014-1028. doi:10.1016/S1474-4422(14)70172-3.
84. Marrie RA, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. Mult Scler 2015;21(3):342-349. doi:10.1177/1352458514564486.
85. Wohleb ES, McKim DB, Sheridan JF, Godbout JP. Monocyte trafficking to the brain with stress and inflammation: a novel axis of immune-to-brain communication that influences mood and behavior. Front Neurosci 2015;8:447. doi:10.3389/fnins.2014.00447.
86. Kern S, Rohleder N, Eisenhofer G, et al. Time mattersVacute stress response and glucocorticoid sensitivity in early multiple sclerosis. Brain Behav Immun 2014;41:82-89. doi:10.1016/j.bbi.2014.04.006.
87. Lovera J, Reza T. Stress in multiple sclerosis: review of new developments and future directions. Curr Neurol Neurosci Rep 2013;13(11):398. doi:10.1007/s11910-013-0398-4.
88. Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014;82(17): 1556-1563. doi:10.1212/WNL. 0000000000000363.
89. Pavisian B, MacIntosh BJ, Szilagyi G, et al. Effects of cannabis on cognition in patients with MS: a psychometric and MRI study. Neurology 2014;82(21):1879-1887. doi:10.1212/WNL.0000000000000446.
90. Cho HJ, Seeman TE, Kiefe CI, et al. Sleep disturbance and longitudinal risk of inflammation: moderating influences of social integration and social isolation in the Coronary Artery Risk Development in Young Adults (CARDIA) study. Brain Behav Immun 2015;46:319-326. doi:10.1016/j.bbi.2015.02.023.
91. Sumowski JF, Rocca MA, Leavitt VM, et al. Searching for the neural basis of reserve against memory decline: intellectual enrichment linked to larger hippocampal volume in multiple sclerosis. Eur J Neurol 2015; doi:10.1111/ene.12662.
92. Zhu N, Jacobs DR Jr, Schreiner PJ, et al. Cardiorespiratory fitness and brain volume and white matter integrity: the CARDIA Study. Neurology 2015;84(23):2347-2353. doi:10.1212/WNL.0000000000001658.
93. Tettey P, Simpson S Jr, Taylor BV, van der Mei IA. Vascular comorbidities in the onset and progression of multiple sclerosis. J Neurol Sci 2014;347(1-2):23-33. doi:10.1016/j.jns.2014.10.020.
94. Tettey P, Simpson S Jr, Taylor B, et al. An adverse lipid profile is associated with disability and progression in disability, in people with MS. Mult Scler 2014;20(13): 1737-1744. doi:10.1177/1352458514533162.